Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer

被引：1

作者：

Nicoletto, Maria Ornella ^{[1
]}

Baldoni, Alessandra ^{[2
]}

Cavallin, Francesco

Grego, Andrea ^{[3
]}

Falci, Cristina ^{[4
]}

Nardin, Margherita ^{[5
]}

Mammano, Enzo ^{[6
]}

Lai, Eleonora ^{[4
]}

Torri, Valter ^{[7
]}

机构：

[1] Ist Oncol Veneto IRCCS, Med Oncol 2, Via Gattamelata 64, I-35121 Padua, Italy

[2] Mirano Hosp, Dept Med Oncol, AULSS Serenissima 3, Mirano, VE, Italy

[3] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy

[4] Ist Oncol Veneto IRCCS, Med Oncol 2, Padua, Italy

[5] Ist Oncol Veneto IRCCS, Radiol Dept, Padua, Italy

[6] Osped St Antonio, Dept Surg, Padua, Italy

[7] Ist Ric Farmacol Mario Negri IRCCS, Lab Methodol Clin Res, Milan, Italy

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2023年 / 15卷

关键词：

BRCA mutated; PARP inhibitors; oxaliplatin; pegylated liposomal doxorubicin; platinum-sensitive epithelial ovarian cancer; PEGYLATED LIPOSOMAL DOXORUBICIN; RECURRENT EPITHELIAL OVARIAN; DOUBLE-BLIND; PHASE-II; MAINTENANCE THERAPY; OPEN-LABEL; OLAPARIB; MULTICENTER; BEVACIZUMAB; CHEMOTHERAPY;

D O I：

10.1177/17588359231173181

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background:The use of PARP inhibitor (PARPi) has shown a considerable benefit in progression-free survival (PFS) in relapsed, platinum-sensitive epithelial ovarian cancer (OC). Objective:Our study aimed to investigate the impact of the last platinum-based chemotherapy treatment in response to PARPi. Design:Retrospective cohort study. Patients and methods:The study involved 96 consecutive, pretreated, platinum-sensitive advanced OC patients. Demographics and clinical data were retrieved from clinical records. PFS and overall survival (OS) were calculated from the start of PARPi. Results:Germline BRCA mutation was investigated in all cases. Platinum-based chemotherapy before PARPi maintenance therapy included pegylated liposomal doxorubicin-oxaliplatin (PLD-Ox) in 46 patients (48%) and other platinum-based chemotherapy in 50 patients (52%). During a median follow-up of 22 months from the beginning of PARPi therapy, 57 patients relapsed (median PFS: 12 months) and 64 patients died (median OS: 23 months). During multivariable analysis, receiving PLD-Ox before PARPi was associated with improved PFS [hazard ratio (HR): 0.46, 95% CI: 0.26-0.82] and OS (HR: 0.48, 95% CI: 0.27-0.83). In 36 BRCA-mutated patients, PLD-Ox was associated with improved PFS (2-year PFS: 70.0% versus 25.0%, p = 0.02). Conclusion:Receiving PLD-Ox before PARPi may improve prognosis in platinum-sensitive advanced OC patients and may provide advantages in the BRCA-mutated subgroup.

引用

页数：10

共 40 条

[11] Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin [J].

Evers, Bastiaan ;

Drost, Rinske ;

Schut, Eva ;

de Bruin, Michiel ;

van der Burg, Eline ;

Derksen, Patrick W. B. ;

Holstege, Henne ;

Liu, Xiaoling ;

van Drunen, Ellen ;

Beverloo, H. Berna ;

Smith, Graeme C. M. ;

Martin, Niall M. B. ;

Lau, Alan ;

O'Connor, Mark J. ;

Jonkers, Jos .

CLINICAL CANCER RESEARCH, 2008, 14 (12) :3916-3925

[12] Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. [J].

Fong, Peter C. ;

Boss, David S. ;

Yap, Timothy A. ;

Tutt, Andrew ;

Wu, Peijun ;

Mergui-Roelvink, Marja ;

Mortimer, Peter ;

Swaisland, Helen ;

Lau, Alan ;

O'Connor, Mark J. ;

Ashworth, Alan ;

Carmichael, James ;

Kaye, Stan B. ;

Schellens, Jan H. M. ;

de Bono, Johann S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) :123-134

[13] Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study [J].

Gelmon, Karen A. ;

Tischkowitz, Marc ;

Mackay, Helen ;

Swenerton, Kenneth ;

Robidoux, Andre ;

Tonkin, Katia ;

Hirte, Hal ;

Huntsman, David ;

Clemons, Mark ;

Gilks, Blake ;

Yerushalmi, Rinat ;

Macpherson, Euan ;

Carmichael, James ;

Oza, Amit .

LANCET ONCOLOGY, 2011, 12 (09) :852-861

[14] Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer [J].

Gonzalez-Martin, A. ;

Pothuri, B. ;

Vergote, I. ;

DePont Christensen, R. ;

Graybill, W. ;

Mirza, M. R. ;

McCormick, C. ;

Lorusso, D. ;

Hoskins, P. ;

Freyer, G. ;

Baumann, K. ;

Jardon, K. ;

Redondo, A. ;

Moore, R. G. ;

Vulsteke, C. ;

O'Cearbhaill, R. E. ;

Lund, B. ;

Backes, F. ;

Barretina-Ginesta, P. ;

Haggerty, A. F. ;

Rubio-Perez, M. J. ;

Shahin, M. S. ;

Mangili, G. ;

Bradley, W. H. ;

Bruchim, I. ;

Sun, K. ;

Malinowska, I. A. ;

Li, Y. ;

Gupta, D. ;

Monk, B. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) :2391-2402

[15] Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and-2 Mutant Tumors [J].

Jones, Philip ;

Altamura, Sergio ;

Boueres, Julia ;

Ferrigno, Federica ;

Fonsi, Massimiliano ;

Giomini, Claudia ;

Lamartina, Stefania ;

Monteagudo, Edith ;

Ontoria, Jesus M. ;

Orsale, Maria Vittoria ;

Palumbi, Maria Cecilia ;

Pesci, Silvia ;

Roscilli, Giuseppe ;

Scarpelli, Rita ;

Schultz-Fademrecht, Carsten ;

Toniatti, Carlo ;

Rowley, Michael .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (22) :7170-7185

[16] Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation [J].

Kaufman, Bella ;

Shapira-Frommer, Ronnie ;

Schmutzler, Rita K. ;

Audeh, M. William ;

Friedlander, Michael ;

Balmana, Judith ;

Mitchell, Gillian ;

Fried, Georgeta ;

Stemmer, Salomon M. ;

Hubert, Ayala ;

Rosengarten, Ora ;

Steiner, Mariana ;

Loman, Niklas ;

Bowen, Karin ;

Fielding, Anitra ;

Domchek, Susan M. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03) :244-250

[17] Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer [J].

Kaye, Stan B. ;

Lubinski, Jan ;

Matulonis, Ursula ;

Ang, Joo Ern ;

Gourley, Charlie ;

Karlan, Beth Y. ;

Amnon, Amit ;

Bell-McGuinn, Katherine M. ;

Chen, Lee-May ;

Friedlander, Michael ;

Safra, Tamar ;

Vergote, Ignace ;

Wickens, Mark ;

Lowe, Elizabeth S. ;

Carmichael, James ;

Kaufman, Bella .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04) :372-379

[18] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial [J].

Ledermann, Jonathan ;

Harter, Philipp ;

Gourley, Charlie ;

Friedlander, Michael ;

Vergote, Ignace ;

Rustin, Gordon ;

Scott, Clare L. ;

Meier, Werner ;

Shapira-Frommer, Ronnie ;

Safra, Tamar ;

Matei, Daniela ;

Fielding, Anitra ;

Spencer, Stuart ;

Dougherty, Brian ;

Orr, Maria ;

Hodgson, Darren ;

Barrett, J. Carl ;

Matulonis, Ursula .

LANCET ONCOLOGY, 2014, 15 (08) :852-861

[19] Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial [J].

Ledermann, Jonathan A. ;

Embleton, Andrew C. ;

Raja, Fharat ;

Perren, Timothy J. ;

Jayson, Gordon C. ;

Rustin, Gordon J. S. ;

Kaye, Stan B. ;

Hirte, Hal ;

Eisenhauer, Elizabeth ;

Vaughan, Michelle ;

Friedlander, Michael ;

Gonzalez-Martin, Antonio ;

Stark, Daniel ;

Clark, Elizabeth ;

Farrelly, Laura ;

Swart, Ann Marie ;

Cook, Adrian ;

Kaplan, Richard S. ;

Parmar, Mahesh K. B. .

LANCET, 2016, 387 (10023) :1066-1074

[20] Epithelial ovarian cancer [J].

Lheureux, Stephanie ;

Gourley, Charlie ;

Vergote, Ignace ;

Oza, Amit M. .

LANCET, 2019, 393 (10177) :1240-1253

← 1 2 3 4 →